In Phase C, members will receive ABBV-744 and oral navitoclax. In Phase D, members will get ABBV-744 and ruxolitinib. Members will obtain treatment until condition progression or even the individuals are not able to tolerate the study drugs. Attainable new approaches for your prognosis and treatment of AML. (A) The https://randallc555zlx0.liberty-blog.com/profile